JDRF partner Selecta is developing a new technology that could lead to a vaccine for T1D.
In an article recently published in Proceedings of the National Academy of Sciences, researchers described the technology which uses nanoparticles to stop the autoimmune attack on insulin-producing beta cells in the pancreas.
This novel technology involves the creation of tiny packages of nanoparticles that contain special immune-modulating agents and T1D antigens. These packages are then targeted towards specialised cells in the immune system, to teach them to tolerate T1D antigens, rather than beginning the autoimmune attack that leads to type 1 diabetes.
The success of this technology in its initial laboratory tests is very promising. JDRF has recently renewed its partnership with Selecta in conjunction with pharmaceutical company Sanofi, and testing of the new technology will now begin in mouse models of type 1 diabetes.
If successful in mouse models the next step could be human clinical trials, and ultimately the development of a vaccine to prevent the type 1 diabetes from occurring.
Read the full journal article here.